John Miller

Corporate Officer/Principal at JAZZ PHARMACEUTICALS PLC

Health Technology

Consumer Services

Profile

John Miller is currently the Senior Vice President-Corporate Strategy at Jazz Pharmaceuticals Plc.
Prior to his current position, he worked as the Director-US & Global Marketing at Alexion Pharmaceuticals, Inc. in 2012 and as the Director-Strategic Marketing at Enobia Pharma, Inc. from 2011 to 2012.
Mr. Miller completed his undergraduate degree at the University of Mississippi and holds an MBA from the Questrom School of Business.

John Miller active positions

Companies	Position	Start
JAZZ PHARMACEUTICALS PLC	Corporate Officer/Principal	2015-01-31

All active positions of John Miller

Former positions of John Miller

Companies	Position	End
ALEXION PHARMACEUTICALS, INC.	Corporate Officer/Principal	2012-07-31
Enobia Pharma, Inc. Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.	Corporate Officer/Principal	2012-01-31

See the detail of John Miller's experience

Training of John Miller

University of Mississippi	Undergraduate Degree
Questrom School of Business	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of John Miller's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
JAZZ PHARMACEUTICALS PLC	Health Technology

Private companies	2
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.	Health Technology
Enobia Pharma, Inc. Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.	Health Technology